Table 3.
Clinical trials involving chemokine inhibitors for cancer treatment.
| Target | Molecule | Cancer Type | Status | References | Identifier |
|---|---|---|---|---|---|
| CCR2 | PF-04136309 + Abraxane + Gemcitabine | Metastatic pancreatic ductal adenocarcinoma | Phase Ib/II | [136] | NCT02732938 |
| PF-04136309 + FOLFIRINOX | Advanced pancreatic ductal adenocarcinoma | Phase II | [137] | NCT01413022 | |
| CCX872 + FOLFIRINOX | Pancreatic adenocarcinoma | Phase Ib | [138] | NCT02345408 | |
| CCL2 | Carlumab | Solid tumors | Phase I | [139] | NCT00537368 |
| Metastatic prostate cancer | Phase II | [140] | NCT00992186 | ||
| CCR4 | Mogamulizumab | Relapsed adult T cell leukaemia | Approved in Japan | [141] | |
| Cutaneous T cell lymphoma | Phase III | [142] | NCT01728805 | ||
| Advanced solid tumors | Phase I/II | [92,143] | NCT02281409 | ||
| Mogamulizumab + Nivolumab | Advanced or metastatic solid tumors | Phase I | [144] | NCT02476123 | |
| CCR5 | Maraviroc | Refractory colorectal cancer | Phase I | [145] | NCT01736813 |
| Maraviroc + Pembrolizumab | Refractory MSS-colorectal cancer. | Phase I | [143] | NCT03274804 | |
| Maraviroc + Ipilmumab + Nivolumab | Metastatic colon and pancreatic cancer | Phase I | [143] | NCT04721301 | |
| Vicriviroc + Pembrolizumab | Metastatic MSS-colorectal cancer. | Phase II | [143] | NCT03631407 | |
| Leronlimab + Carboplatin | Metastatic triple-negative breast cancer | Phase Ib/II | [143] | NCT04313075 | |
| Leronlimab | Solid tumors | Phase II | [143] | NCT04504942 | |
| CXCR2 | AZD5069 + enzalutamide | Prostate cancer | Phase II | [143] | NCT03177187 |
| AZD5069/AZD9150 + MEDI4736 | Head and Neck Squamous cell carcinoma | Phase Ib/II | [143] | NCT02499328 | |
| AZD5069+ MEDI4736 | Pancreatic ductal carcinoma | Phase Ib/II | [143] | NCT02583477 | |
| Reparixin + Paclitaxel | Metastatic Triple-Negative Breast cancer | Phase II | [143] | NCT02370238 | |
| HER2 Negative Breast Cancer | Phase I | [143] | NCT02001974 | ||
| Reparixin | Early breast cancer | Phase II | [143] | NCT01861054 | |
| Navarixin + Pembrolizumab | NSCLC; Castration resistant prostate cancer; MSS- colorectal cancer | Phase II | [143] | NCT03473925 | |
| SX-682 + Pembrolizumab | Stage III and IV melanomas | Phase I | [143] | NCT03161431 | |
| CXCR4 | Plerixafor (AMD3100) | Acute myeloid leukaemia | Phase I/II | [146] | NCT00512252 |
| PF-06747143 (humanized mab) | Acute myeloid leukaemia | Phase I | [147] | NCT02954653 | |
| Ulocuplumab + lenalidomide + dexamethasone | Relapsed/refractory myeloma | Phase Ib/II | [148] | NCT01359657 | |
| Plerixafor + temozolomide + radiation | Brain cancer | Phase I/II | [149] | NCT01977677 | |
| USL311 + Lomustine | Recurrent Glioblastoma Multiforme | Phase I/II | [143] | NCT02765165 | |
| LY2510924LY | Solid cancers | Phase I/II | [143] | NCT02737072 | |
| Balixafortide | Metastatic breast cancer | Phase I | [150] | NCT01837095 |
MSS—Microsatellite Stable; HER2—Receptor tyrosine-protein kinase erbB-2; NSCLC—Non-small cell lung cancer.